Mattia Falcone1,2, Alejandro Huerta Uribe1, Vasileios Papalazarou1, Alice C Newman1, Dimitris Athineos3, Katrina Stevenson1, Charles-Etienne Gabriel Sauvé4, Yajing Gao4,5, Jin K Kim4, Michael Del Latto6, Maria Kierstead6, Chao Wu4,5, J Joshua Smith4,5, Paul B Romesser6,7, Anthony J Chalmers1, Karen Blyth1,3, Oliver D K Maddocks8. 1. School of Cancer Sciences, Wolfson Wohl Cancer Research Centre, University of Glasgow, Glasgow, UK. 2. Division of Oncogenomics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. 3. Cancer Research UK Beatson Institute, Glasgow, UK. 4. Colorectal Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 5. Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA. 6. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA. 7. Early Drug Development Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA. 8. School of Cancer Sciences, Wolfson Wohl Cancer Research Centre, University of Glasgow, Glasgow, UK. Oliver.Maddocks@glasgow.ac.uk.
Abstract
BACKGROUND: Cellular metabolism is an integral component of cellular adaptation to stress, playing a pivotal role in the resistance of cancer cells to various treatment modalities, including radiotherapy. In response to radiotherapy, cancer cells engage antioxidant and DNA repair mechanisms which mitigate and remove DNA damage, facilitating cancer cell survival. Given the reliance of these resistance mechanisms on amino acid metabolism, we hypothesised that controlling the exogenous availability of the non-essential amino acids serine and glycine would radiosensitise cancer cells. METHODS: We exposed colorectal, breast and pancreatic cancer cell lines/organoids to radiation in vitro and in vivo in the presence and absence of exogenous serine and glycine. We performed phenotypic assays for DNA damage, cell cycle, ROS levels and cell death, combined with a high-resolution untargeted LCMS metabolomics and RNA-Seq. RESULTS: Serine and glycine restriction sensitised a range of cancer cell lines, patient-derived organoids and syngeneic mouse tumour models to radiotherapy. Comprehensive metabolomic and transcriptomic analysis of central carbon metabolism revealed that amino acid restriction impacted not only antioxidant response and nucleotide synthesis but had a marked inhibitory effect on the TCA cycle. CONCLUSION: Dietary restriction of serine and glycine is a viable radio-sensitisation strategy in cancer.
BACKGROUND: Cellular metabolism is an integral component of cellular adaptation to stress, playing a pivotal role in the resistance of cancer cells to various treatment modalities, including radiotherapy. In response to radiotherapy, cancer cells engage antioxidant and DNA repair mechanisms which mitigate and remove DNA damage, facilitating cancer cell survival. Given the reliance of these resistance mechanisms on amino acid metabolism, we hypothesised that controlling the exogenous availability of the non-essential amino acids serine and glycine would radiosensitise cancer cells. METHODS: We exposed colorectal, breast and pancreatic cancer cell lines/organoids to radiation in vitro and in vivo in the presence and absence of exogenous serine and glycine. We performed phenotypic assays for DNA damage, cell cycle, ROS levels and cell death, combined with a high-resolution untargeted LCMS metabolomics and RNA-Seq. RESULTS: Serine and glycine restriction sensitised a range of cancer cell lines, patient-derived organoids and syngeneic mouse tumour models to radiotherapy. Comprehensive metabolomic and transcriptomic analysis of central carbon metabolism revealed that amino acid restriction impacted not only antioxidant response and nucleotide synthesis but had a marked inhibitory effect on the TCA cycle. CONCLUSION: Dietary restriction of serine and glycine is a viable radio-sensitisation strategy in cancer.
Authors: Pierre Danhier; Christophe J De Saedeleer; Oussama Karroum; Géraldine De Preter; Paolo E Porporato; Bénédicte F Jordan; Bernard Gallez; Pierre Sonveaux Journal: Semin Radiat Oncol Date: 2013-10 Impact factor: 5.934
Authors: Gaganpreet S Tiwana; Remko Prevo; Francesca M Buffa; Sheng Yu; Daniel V Ebner; Alison Howarth; Lisa K Folkes; Balam Budwal; Kwun-Ye Chu; Lisa Durrant; Ruth J Muschel; W Gillies McKenna; Geoff S Higgins Journal: Oncotarget Date: 2015-03-20
Authors: Smrithi S Menon; Medha Uppal; Subeena Randhawa; Mehar S Cheema; Nima Aghdam; Rachel L Usala; Sanchita P Ghosh; Amrita K Cheema; Anatoly Dritschilo Journal: Front Oncol Date: 2016-02-02 Impact factor: 6.244
Authors: Eva Lindell Jonsson; Ida Erngren; Mikael Engskog; Jakob Haglöf; Torbjörn Arvidsson; Mikael Hedeland; Curt Petterson; Göran Laurell; Marika Nestor Journal: Front Oncol Date: 2019-08-30 Impact factor: 6.244